The Role of TNF Superfamily Member 13 in the Progression of IgA Nephropathy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
TNF superfamily member 13 (TNFSF13) has been identified as a susceptibility gene for IgA nephropathy in recent genetic studies. However, the role of TNFSF13 in the progression of IgA nephropathy remains unresolved. We evaluated two genetic polymorphisms (rs11552708 and rs3803800) and plasma levels of TNFSF13 in 637 patients with IgA nephropathy, and determined the risk of ESRD according to theses variable. Neither of the examined genetic polymorphisms associated with a clinical outcome of IgA nephropathy. However, high plasma levels of TNFSF13 increased the risk of ESRD. To explore the causal relationship and underlying mechanism, we treated B cells from patients (n=21) with or without recombinant human TNFSF13 (rhTNFSF13) and measured the expression of IgA and galactose-deficient IgA (GdIgA) using ELISA and flow cytometry. Treatment with rhTNFSF13 significantly increased the total IgA level among B cells, and TNFSF13 receptor blockade abrogated this increase. Furthermore, the absolute levels of GdIgA increased with rhTNFSF13 treatment, but the total IgA-normalized levels did not change. Both RNA sequencing and quantitative PCR results showed that rhTNFSF13 did not alter the expression of glycosyltransferase enzymes. These results suggest that high plasma TNFSF13 levels associate with a worse prognosis of IgA nephropathy through the relative increase in GdIgA levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929
Coppo (2007) · doi:10.1681/asn.2006040347 · Cited by 256
Corticosteroid therapy in IgA nephropathy
Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111112 · Cited by 190
Cited by
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Mathur, M., Barratt, J., Chacko, B., Chan, T. M., Kooienga, L., Oh, K.-H., Sahay, M., Suzuki, Y., Wong, M. G., Yarbrough, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305635 · Cited by 239
The expanding role of biomarkers in the management of IgA nephropathy
Jain, K., & Rizk, D. V. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.004 · Cited by 6
“69,72,73 With the rise of investigational agents targeting BAFF and/or APRIL for the treatment of IgAN (e.g., atacicept, povetacicept, and sibeprenlimab), several pre-liminary trials have shown that APRIL inhibition, with or without BAFF inhibition, is associated with reductions in proteinuria and…”
Cheung, C. K., & Mariani, L. H. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.003 · Cited by 2
Metadata
- Authors
- Han, S. S., Yang, S. H., Choi, M., Kim, H.-R., Kim, K., Lee, S., Moon, K. C., Kim, J. Y., Lee, H., Lee, J. P., Jung, J. Y., Kim, S., Joo, K. W., Lim, C. S., Kang, S.-W., Kim, Y. S., & Kim, D. K.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-04-11
- Volume
- 27
- Issue
- 11
- Pages
- 3430-3439
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2324533035
- Cited by
- 62
- References
- 3
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.